In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying opportunity?

What Happened? Shares of biotech company Regeneron (NASDAQ:REGN) fell 19% in the afternoon session after the company announced mixed results from its Phase 3 trials for itepekimab, an experimental ...

Regeneron Pharma stock has been in a persistent downtrend for over 280 days. Here's why you should avoid REGN.

Regeneron (REGN) is expected to deliver a year-over-year decline in earnings on higher ... a powerful factor that could impact its near-term stock price. The earnings report, which is expected ...

Regeneron is bearing the brunt of investors of late as Eylea’s sales witness a rapid decline. Earlier, the stock took a hit after an unfavorable ruling in its lawsuit against Amgen in the United ...

The stock's fall snapped a two-day winning streak.

The company’s stock, currently trading at $529.24 ... Eylea has been a significant revenue driver for Regeneron, and its decline poses a substantial risk to the company’s financial performance.

Regeneron Pharmaceuticals' (NASDAQ:REGN) stock is trading in the red premarket ... COVID‑19 antibody therapy REGEN-COV saw a decline of -3.52% Y/Y to $613.2M in global sales, which consisted ...

One stock in particular has grabbed my attention during this selloff. Regeneron's decline has been epic, and now may be the time to buy. Regeneron's stock, REGN, was taken to the woodshed.

Revenue declined 4% from the prior year, as Regeneron struggled to offset the double-digit decline in net product ... down 6.8% from previous close. The stock market overreacts to news, and ...